Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated in the trial, and none of them contracted HIV, signaling a potential game-changer for HIV prevention. All Gilead has to do now is to replicate the…
In this StockCharts TV video, Mary Ellen reviews the broader markets, takes a close look at NVDA and other year-to-date…
Moving averages are a crucial charting tool, but many of us aren’t getting the most out of them. In…
Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading…
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse…
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like…
Last week, the broader market Indices hit another new high on Thursday before pulling back into Friday’s close. Not…
The Dow Jones Industrial Average ($INDU) may not be the comprehensive measure of the US economy it once was…